Pharmaceuticals News and Research

RSS

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Professional athletes with repetitive head trauma and possibly others with a history of head injuries many years previously may be prone the development of a motor neuron disease similar to amyotrophic lateral sclerosis (ALS or "Lou Gehrig's disease"), reports a study in the September Journal of Neuropathology & Experimental Neurology, official journal of the American Association of Neuropathologists, Inc.

18 Aug 2010

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and MonoSol Rx, the leader in developing and manufacturing pharmaceutical films based on its proprietary PharmFilm drug delivery technology, today announced the filing of a provisional US patent application for "Nanoparticle Film Delivery Systems." The applications submitted to the United States Patent and Trademark Office (USPTO) relate to therapeutic uses of nanoparticle-based proteins and peptides delivered in pharmaceutical films.

18 Aug 2010

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living.

18 Aug 2010

Life Technologies, CEVEC Pharmaceuticals sign licensing agreement to supply CAP-T expression kits

CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation, a leading provider of innovative life science solutions based in Carlsbad, California. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC's proprietary CAP-T cells to the global life science research community.

18 Aug 2010

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate is ZC-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease.

18 Aug 2010

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012.

18 Aug 2010

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations, announced results for the fiscal first quarter ended June 30, 2010.

17 Aug 2010

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

17 Aug 2010

TRI awarded RSC contract to support domestic, international clinical research programs

Technical Resources International, Inc. is pleased to announce that TRI has been awarded the Regulatory Support Center contract by the U.S. National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health, Department of Health and Human Services.

17 Aug 2010

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

Europe's most promising oncology biotechs and other key stakeholders will gather in Oslo, Norway, September 15-17 for the 2nd European Cancer Cluster Meeting (ECCP 2010). Co-hosted by the Oslo Cancer Cluster and the Cancer-Bio-Santé Cluster from Toulouse, the two-day meeting is a unique partnering opportunity for oncology biotech companies, business development and licensing executives from the pharmaceutical industry and investors, as well as innovative researchers and clinicians.

17 Aug 2010

PRA International to host audio conference on CV drug development strategy

PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

17 Aug 2010

MMV joins Pool for Open Innovation against neglected tropical diseases

The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).

17 Aug 2010

Studies provide evidence for new approach to MRSA vaccines

Two recent studies provide evidence for a new approach to vaccines to prevent infections caused by drug-resistant Staphylococcus aureus -- better known as MRSA - the leading cause of skin and soft tissue, bloodstream and lung infections in the United States. One demonstrates a way to counteract the bacteria's knack for evading the immune system. The other shows how to disrupt the germ's tissue-damaging mechanism.

17 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

FDA considers dropping Avastin approval, approves five-day emergency contraception pill

The Food and Drug Administration is considering revoking its approval of a last-ditch breast cancer drug over the debate on "medical spending and effectiveness that flared during the battle over health-care reform," The Washington Post reports. "The [FDA] is reviewing the recommendation of influential scientific advisers to revoke authorization of the drug to treat metastatic breast cancer.

17 Aug 2010

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done.

17 Aug 2010

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

CEL-SCI reported a net loss for the three months ended June 30, 2010 of ($0.6) million versus a loss of ($6.2) million during the same three months in fiscal year 2009. Net loss per basic share was ($0.00) for the three months ended June 30, 2010 versus a loss per basic share of ($0.05) during the same three months in fiscal year 2009. The loss during the quarter ended June 30, 2010 was reduced by a gain on derivative instruments of $2.75 million.

17 Aug 2010

Pernix Therapeutics reports decrease in net sales for 2010 second quarter

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced results for the quarter and six months ended June 30, 2010.

17 Aug 2010

Global vaccine sales up 16% in 2009, report says

Global vaccine sales "grew by a healthy 16 percent last year, when sales shot up to $22.1 billion, healthcare market research publisher Kalorama Information reported Friday," according to the Associated Press. Kalorama is also forecasting sales "will rise at a compound annual rate of 9.7 percent during the next five years," (Johnson, 8/14).

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Pharmaceuticals News and Research

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

Lilly to halt development of potential Alzheimer's disease drug semagacestat

Life Technologies, CEVEC Pharmaceuticals sign licensing agreement to supply CAP-T expression kits

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

BioMarin commences Phase 3b study of Kuvan's neuropsychiatric effects in phenylketonuria patients

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

TRI awarded RSC contract to support domestic, international clinical research programs

European Cancer Cluster Meeting 2010 to be held September 15-17 in Oslo, Norway

PRA International to host audio conference on CV drug development strategy

MMV joins Pool for Open Innovation against neglected tropical diseases

Studies provide evidence for new approach to MRSA vaccines

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

FDA considers dropping Avastin approval, approves five-day emergency contraception pill

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

Pernix Therapeutics reports decrease in net sales for 2010 second quarter

Global vaccine sales up 16% in 2009, report says

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence